All In Biotech

Drug Trial Radar · NCT05695508

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants With Newly Diagnosed Transplant Eligible Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Dec 1, 2022

Primary completion

Sep 15, 2028

Study completion Sep 15, 2029

Sponsor

Lead sponsor
University of Heidelberg Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Janssen Research & Development, LLC; Deutsche Studiengruppe Multiples Myelom (DSMM)
First posted
Jan 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma OBJECTIVES: To evaluate the safety and tolerability of teclistamab-, talquetamab-, and JNJ-79635322-based combination regimens over the entire treatment phase for each arm, in participants with ND-TEMM To evaluate the efficacy of teclistamab- and talquetamab-based combination regimens as induction and post-transplant maintenance treatments; JNJ-79635322-based combinations as induction and as replacement for HDT+ASCT following induction; and teclistamab in combination with talquetamab

Conditions

  • Multiple Myeloma

Interventions

  • Teclistamab (Tec)Drug

    Subcutaneous administration of Teclistamab

  • DaratumumabDrug

    Subcutaneous administration of Daratumumab

  • DexamethasoneDrug

    administered i.v. or orally

  • LenalidomideDrug

    Administration oral

  • BortezomibDrug

    Subcutaneous administration

  • TalquetamabDrug

    Subcutaneous administration of Daratumumab

  • JNJ-79635322Drug

    Subcutaneous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. number of incidence and severity of adverse events [safety and tolerability]Time frame: through study completion, up to 28 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Charité University Medicin Berlin

    Berlin, Germany · Recruiting

  • Clinic Chemnitz gGmbH

    Chemnitz, Germany · Recruiting

  • University Clinic Technical University Dresden

    Dresden, Germany · Recruiting

  • University Clinic Düsseldorf

    Düsseldorf, Germany · Recruiting

  • University Clinic Freiburg

    Freiburg im Breisgau, Germany · Recruiting

  • Hamburg University Clinic Eppendorf

    Hamburg, Germany · Recruiting

  • Asklepios Clinic Hamburg Altona

    Hamburg, Germany · Recruiting

  • University Hospital Heidelberg

    Heidelberg, Germany · Recruiting

  • University Clinic Schleswig-Holstein Campus Kiel

    Kiel, Germany · Recruiting

  • Technical University Munich

    Munich, Germany · Recruiting

  • University Würzburg

    Würzburg, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.